Probably, uh, in my, my guess, and this is just a total guess on my part, yeah
Those are individualized, high-stakes conversations that require full disclosure, multidisciplinary collaboration, and explicit consent
More recent DSIP research has been largely preclinical, mechanistic (focused on how DSIP may work biologically rather than whether it produces proven benefits in humans), or exploratory rather than large-scale human outcome research [16][17]
If approved , cagrilintide could become a first-line option in pharmacologic obesity management , especially within aesthetic settings where facial fullness, contouring, and body composition improvements are key patient goals
Important: GHK-Cu is a research compound and is not FDA-approved